MetaCap

Accuray (ARAY) vs SeaStar Medical (ICU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Accuray (ARAY) has outperformed SeaStar Medical (ICU) over the past year, gaining 97.6% versus a loss of 69.3%. Over five years, ARAY leads with a -59.5% price change compared with -100.0% for ICU. Accuray is the larger company by market cap ($6.2 million vs $5.0 million), about 1.3 times the size, while SeaStar Medical is growing revenue faster (+814.1% vs -12.3%).

Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -984.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARAY+97.62%ICU-69.34%
+281%+87%-107%
Nov 21, 20251 yearNov 20, 2026
ARAY-61.79%ICU-99.96%
+30%-38%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARAY versus ICU key metrics
MetricARAYICU
Share price$2.08$0.935
Market cap$6.22M$4.97M
1-day change-2.12%-10.95%
YTD return+153.05%-61.04%
1-year return+97.62%-69.34%
5-year return-59.47%-99.96%
EPS (TTM)$-5.60$-2.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$401.95M$1.23M
Revenue growth (YoY)-12.34%+814.07%
Net income (latest FY)$-49.19M$-12.15M
Gross margin27.73%95.71%
Operating margin-6.58%-986.63%
Net margin-12.24%-984.60%
52-week high$45.20$5.38
52-week low$2.05$0.761
Distance from 52-week high-95.41%-82.62%
Analyst consensusnonenone
Avg. price target upside—+969.52%
Average volume201.35K196.27K
Shares outstanding3.00M5.32M
Employees80918
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARAY has outperformed ICU by 167.0 percentage points over the past year.
  • Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -984.6 cents for SeaStar Medical.
  • SeaStar Medical grew revenue faster in its latest fiscal year (+814.07% vs -12.34%).

About Accuray

ARAY stock →

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Health Care · Medical/Dental Instruments · 809 employees

About SeaStar Medical

ICU stock →

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.

Health Care · Medical/Dental Instruments · 18 employees

ARAY vs ICU FAQ

Which is bigger, Accuray or SeaStar Medical?

Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $4.97M for SeaStar Medical (ICU).

Which stock has performed better over the past year, ARAY or ICU?

ARAY returned +97.62% over the past 12 months, compared with -69.34% for ICU (price return, excluding dividends). Past performance does not predict future results.

Are Accuray and SeaStar Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons